Martin Gleave
Dr. Martin Gleave is a Canadian surgeon and cancer researcher who was appointed to the Order of Canada in 2018.[1]
Gleave is a co-founder and executive director of the Vancouver Prostate Centre as well as a head of a department at University of British Columbia.
Gleave's team was recognized in 2010 as the first in the world to develop an anti-clusterin agent.[2]
Awards
[edit]- Richard D. Williams MD Prostate Cancer Research Excellence Award[3]
- Eugene Fuller Triennial Prostate Award from the American Urological Association[3]
- Barringer Medal from the American Association of Genitourinary Surgeons[3]
- BC Biotech Innovation and Achievement Award[3]
- BC Innovation Council Frontiers in Research Award[3]
- 2013 Aubrey J. Tingle Prize from Michael Smith Foundation for Health Research[4]
References
[edit]- ^ Li, Wanyee (January 4, 2018). "B.C. doctor inducted into Order of Canada for innovative cancer treatments". Metro News Vancouver. Retrieved January 10, 2018.
- ^ Crawford, Tiffany (August 28, 2010). "New cancer drug will prolong lives, Vancouver scientists say". Vancouver Sun. Retrieved 9 January 2018.
- ^ a b c d e "DR. MARTIN GLEAVE APPOINTED TO THE ORDER OF CANADA". Vancouver Coastal Health Research Institute. Retrieved January 9, 2018.
- ^ "AJT Prize Recognizes Made-In-BC Advances In Prostate Cancer Treatment". msfhr.org. Retrieved January 9, 2018.
 .svg){kind=small}  | This biography related to medicine in Canada is a stub. You can help Wikipedia by expanding it. |